AI 'Dementia Diagnosis' Developer NeuroXT Secures Investment from Samsung Ventures and LG

▤ Summary

NeuroXT, a Korean medical AI company, secured investment from Samsung Ventures and LG after developing Next-CDX, an AI tool that analyzes MRI scans to diagnose Alzheimer’s with roughly 90% accuracy. The company is running clinical studies with Harvard Medical School and Johns Hopkins to predict cognitive improvement from the Alzheimer drug Leqembi, with results due later this year. Earlier work with Johnson & Johnson showed NeuroXT’s model predicted cognitive improvement in 79% of a selected patient group, and the team plans to publish results in an international journal. NeuroXT positions its MRI-based approach as a lower-cost alternative to PET scans, and prior investors include Kakao Ventures, LSK Investment, and Smilegate Investment.

$ Funding

▦ Linked Companies